Atomoxetine + stimulants (any approved ADHD medication)
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout Atomoxetine + stimulants (any approved ADHD medication)
Atomoxetine + stimulants (any approved ADHD medication) is a pre-clinical stage product being developed by Eli Lilly for ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT00540826. Target conditions include ADHD.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00540826 | Pre-clinical | Completed |
Competing Products
20 competing products in ADHD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine | Eli Lilly | Approved | 85 |
| Strattera (atomoxetine) | Eli Lilly | Approved | 85 |
| Atomoxetine + placebo | Eli Lilly | Approved | 85 |
| Atomoxetine Hydrochloride + placebo | Eli Lilly | Approved | 85 |
| atomoxetine (Strattera) | Eli Lilly | Approved | 85 |
| dasotraline + Placebo | Sumitomo Pharma | Phase 3 | 77 |
| dasotraline | Sumitomo Pharma | Phase 1 | 33 |
| dasotraline 4mg | Sumitomo Pharma | Phase 3 | 77 |
| AZD1446 + AZD1446 + AZD1446 + Placebo | AstraZeneca | Phase 2 | 52 |
| Placebo + AZD3480 + AZD3480 | AstraZeneca | Phase 2 | 52 |
| MK0249 + Concerta (methylphenidate) + Placebo | Merck | Phase 2 | 52 |
| Focalin XR | Novartis | Phase 3 | 77 |
| Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo | Novartis | Approved | 85 |
| Dexmethylphenidate HCl extended-release capsules | Novartis | Phase 3 | 77 |
| Methylphenidate hydrochloride | Novartis | Phase 3 | 77 |
| Focalin XR | Novartis | Phase 3 | 77 |
| methylphenidate HCl ERCT + Placebo | Pfizer | Approved | 84 |
| methylphenidate HCl ERCT | Pfizer | Approved | 84 |
| Very Low Dose Quillivant XR + Low Dose Quillivant XR + Moderate Dose Quillivant XR | Pfizer | Approved | 84 |
| Brexpiprazole | Lundbeck | Phase 1 | 30 |